Abstract 1676P
Background
Pancreatic cancer has a poor prognosis compared to many other malignancies. This study evaluated the clinical outcomes of systemic chemotherapy (CMT) in patients with locally advanced and metastatic pancreatic ductal adenocarcinoma (LA/M-PDAC).
Methods
A retrospective, observational chart review was conducted on patients with LA/M-PDAC who underwent CMT between January 2012 and November 2022. The efficacy data (objective response rate [ORR], disease-control rate [DCR], progression-free survival [PFS], and overall survival [OS]) were evaluated and compared using Pearson’s chi-square tests, Kaplan–Meier plots, and log-rank tests.
Results
Out of the 998 patients diagnosed with LA/M-PDAC, 332 (33.3%) received systemic CMT. Among the treatment regimens used, gemcitabine (GEM) was administered most frequently (33.7% of cases). The next most commonly utilized therapies were (m)FOLFIRINOX and GEM plus capecitabine (GEMCAPE), accounting for 27.4% and 26.2% of cases, respectively. Platinum doublets (PlatD) were administered in 9.3% of cases. The ORRs and DCRs of the four regimens differed significantly (for GEM, GEMCAPE, (m)FOLFIRINOX, and PlatD, the ORRs were 4.5%, 10.3%, 23.1%, 19.4%, respectively, with P < 0.0001; the DCRs were 38.4%, 52.9%, 73.6%, and 54.8%, respectively, with P < 0.0001). Patients who received combination CMTs had significantly longer median PFSs than those who received GEM alone (PFS = 4.93 months for GEMCAPE, 9 months for (m)FOLFIRINOX, 9.43 months for PlatD, and 3.87 months for GEM). When comparing GEMCAPE with (m)FOLFIRINOX, the median PFS was significantly lower in the GEMCAPE group (PFS = 4.93 vs 9.0 months; HR = 0.53; P < 0.0001). However, no significant differences were observed in the median OS rates of the four regimens in a multivariate Cox proportional-hazards model analysis. The frequency of treatment-related grade 3 or 4 adverse events was higher in the (m)FOLFIRINOX group, followed by the GEMCAPE group.
Conclusions
This study revealed that FOLFIRINOX exhibited higher ORR, DCR, and PFS rates than GEM or GEMCAPE. Nevertheless, no survival advantage was detected in the FOLFIRINOX groups, suggesting the influence of subsequent therapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
K. Korphaisarn: Financial Interests, Personal, Invited Speaker: Roche, Amgen, AstraZeneca, MSD; Non-Financial Interests, Principal Investigator: MSD, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22